AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 6 - (NewsRx.com & NewsRx.net) -- A reseracher reviews biologic therapy for brain cancers in a recent issue of the Yonsei Medical Journal.
According to a study from the United States, "The overall goal of our research projects is to develop effective immunotherapeutic regimens, particularly combining vaccine and gene therapy/cell therapy strategies."
"For the development of clinically effective immunotherapy for brain cancers, the following issues are considered to be particularly important: induction of effective immune responses against tumors (afferent arm of the immune response); delivery of immune effector cells to the target tumor sites and maintaining the activity of the effector cells (efferent arm); and for specific and safe immunotherapy, specific brain tumor rejection antigens have to be identified; feasibility, safety, and efficacy need to be tested in a series of clinical trials," stated Hideho Okada at the University of Pittsburgh.
"The following presentation summarizes my research projects and demonstrates how each plan will fit in the whole schema of designing successful immunotherapeutic strategies for brain cancers," said Okada. "In this presentation, I ...